These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 32592923)

  • 1. Health technology assessment with risk aversion in health.
    Lakdawalla DN; Phelps CE
    J Health Econ; 2020 Jul; 72():102346. PubMed ID: 32592923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk preferences over health: Empirical estimates and implications for medical decision-making.
    Mulligan K; Baid D; Doctor JN; Phelps CE; Lakdawalla DN
    J Health Econ; 2024 Mar; 94():102857. PubMed ID: 38232447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods to Adjust Willingness-to-Pay Measures for Severity of Illness.
    Phelps CE; Lakdawalla DN
    Value Health; 2023 Jul; 26(7):1003-1010. PubMed ID: 36796478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states.
    Lipman SA; Brouwer WBF; Attema AE
    Eur J Health Econ; 2019 Apr; 20(3):419-426. PubMed ID: 30229374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach.
    Lakdawalla DN; Phelps CE
    Value Health; 2021 Feb; 24(2):244-249. PubMed ID: 33518031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis.
    Kowal S; Ng CD; Schuldt R; Sheinson D; Cookson R
    Value Health; 2023 Feb; 26(2):216-225. PubMed ID: 36192293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE).
    Lakdawalla DN; Phelps CE
    Eur J Health Econ; 2022 Apr; 23(3):433-451. PubMed ID: 34495445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A principled approach to non-discrimination in cost-effectiveness.
    Lakdawalla DN; Doctor JN
    Eur J Health Econ; 2024 Feb; ():. PubMed ID: 38411845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.
    Igarashi A; Azuma MK; Zhang Q; Ye W; Sardesai A; Folse H; Chavan A; Tomita K; Tahami Monfared AA
    Neurol Ther; 2023 Aug; 12(4):1133-1157. PubMed ID: 37188886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer.
    Zaim R; Redekop WK; Uyl-de Groot CA
    Front Oncol; 2023; 13():1027659. PubMed ID: 36969040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.
    Tahami Monfared AA; Ye W; Sardesai A; Folse H; Chavan A; Kang K; Zhang Q
    Neurol Ther; 2023 Jun; 12(3):795-814. PubMed ID: 36929345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial analysis and factors associated with transcatheter aortic valve implantation in Portugal: a retrospective analysis from 2015 to 2017.
    Avelar FG; Emmerick I; Alves J
    BMJ Open; 2023 Feb; 13(2):e070715. PubMed ID: 36746542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study.
    Zhang M; Bao Y; Yang Y; Kimber M; Levine M; Xie F
    Pharmacoeconomics; 2023 Apr; 41(4):439-455. PubMed ID: 36729295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?
    Postma MJ; Noone D; Rozenbaum MH; Carter JA; Botteman MF; Fenwick E; Garrison LP
    Orphanet J Rare Dis; 2022 Apr; 17(1):157. PubMed ID: 35382853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?
    Chhatwal J; Basu A
    Value Health; 2022 May; 25(5):697-698. PubMed ID: 35315330
    [No Abstract]   [Full Text] [Related]  

  • 16. Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States.
    Prados MJ; Liu Y; Jun H; Lam J; Mattke S
    Alzheimers Dement; 2022 Jan; 18(1):142-151. PubMed ID: 35142025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.
    Elbasha EH
    Pharmacoeconomics; 2022 May; 40(5):497-507. PubMed ID: 35137340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate risk preferences in the quality-adjusted life year model.
    Attema AE; Frasch JJ; L'Haridon O
    Health Econ; 2022 Feb; 31(2):382-398. PubMed ID: 34796588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors.
    Ito K; Chapman R; Pearson SD; Tafazzoli A; Yaffe K; Gurwitz JH
    JAMA Netw Open; 2021 Oct; 4(10):e2129392. PubMed ID: 34677596
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.